BioSpace News Archive

Aulos Bioscience to Present New Preclinical Data on Computationally Evolved IL-2 Human Antibody AU-007 at 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting

UroGen Pharma Ltd. today announced The Journal of Urology® published results from the Phase 2b OPTIMA II trial, a Phase 2b, open-label, single-arm trial studying UGN-102 (mitomycin) for intravesical solution as primary non-surgical therapy for low-grade intermediate risk non-muscle invasive bladder cancer (LG IR-NMIBC).

Twist Bioscience Corporation today announced an expansion of its expert-led Alliance Panel product offering.

Better Choice Company today announced that the Company will participate in the LD Micro Main Event and the Dawson James Small Cap Growth Conference in October 2021.

Berkeley Lights, Inc. announced Genovac’s expansion into cell line development capabilities using the Berkeley Lights Beacon® system and Opto™ CLD workflow.

Cintex Services, LLC and Senores Pharmaceuticals, Inc. announce the launch of Chlorzoxazone Tablets USP, 250 mg, a therapeutic equivalent version of Paraflex (Chlorzoxazone) 250 mg in the U.S. market.

Tesis Labs, a leader in targeted genetic sequencing, announced $20 million of growth equity financing at a post-money valuation of $520 million.

Emerge Diagnostics, a HealthTech firm specializing in soft tissue injury management, today announced enhancements to its breakthrough Electrodiagnostic Functional Assessment (EFA) programs, which will make it possible to deliver comprehensive functional assessments and objective Independent Medical Exams (IMEs) remotely via telemedicine.

Zymeworks Inc. and ALX Oncology Holdings Inc. today announced the first patient has been dosed in an open-label, multi-center Phase 1b/2 clinical trial conducted by Zymeworks.

Genentech, a member of the Roche Group, announced that new Ocrevus® and EnspryngTM data will be presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis from October 13 – 15, 2021.